Abstract:Retinoid X receptor alpha (RXRα) is an important therapeutic target of cancer. Recently, small molecules ( e.g., XS-060 and its derivatives), which can significantly induce RXRα-dependent mitotic arrest by inhibiting p RXRα-PLK1 interaction, have been demonstrated as excellent anticancer agents. To further obtain novel RXR-targeted antimitotic agents with excellent bioactivity and drug-like properties, we herein synthesized two new series of bipyridine amide derivatives with XS-060 as the lead compound. In the reporter gene assay, most synthesized compounds showed antagonistic activity against RXRα. The most active compound, bipyridine amide B9 (BPA-B9) , showed better activity than XS-060 , with excellent RXRα-binding affinity ( K D = 39.29 ± 1.12 nM) and anti-proliferative activity against MDA-MB-231 (IC 50 = 16 nM, SI > 3). Besides, a docking study revealed a proper fitting of BPA-B9 into the coactivator binding site of RXRα, rationalizing its potent antagonistic effect on RXRα transactivation. Further, the mechanism studies revealed that the anticancer activity of BPA-B9 was dependent on its cellular RXRα-targeted mechanism, such as inhibiting p RXRα-PLK1 interaction and inducing RXRα-dependent mitotic arrest. Besides, BPA-B9 displayed better pharmacokinetics than the lead XS-060. Further, animal assays indicated BPA-B9 had significant anticancer efficacy in vivo with no considerable side effects. Together, our study reveals a novel RXRα ligand BPA-B9 targeting the p RXRα-PLK1 interaction, with great potential as a promising anticancer drug candidate for further development.

Discovery of 4-Chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides As Novel RET Kinase Inhibitors

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose

Discovery of 3,5-Diaryl-1h-pyrazol-based Ureas As Potent RET Inhibitors.

Synthesis and Structure–activity Relationship Study of Pyrazolo[3,4-D]pyrimidines As Tyrosine Kinase RET Inhibitors

Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors

Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer

Structure-based design and synthesis of 5-benzyl-2-phenylpyrimidin-4(3H)-one derivatives as novel MEK1 inhibitors

New 5,6,7,8‐Tetrahydro‐isoquinolines Bearing 2‐Nitrophenyl Group Targeting RET Enzyme: Synthesis, Anticancer Activity, Apoptotic Induction and Cell Cycle Arrest

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives Possessing Benzotriazole Moiety As FAK Inhibitors with Anticancer Activity.

Synthesis, Biological Evaluation of Novel 4,5-Dihydro-2h-pyrazole 2-Hydroxyphenyl Derivatives As BRAF Inhibitors.

Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors

Discovery of Novel 5,6-Dihydro-4 H -pyrido[2,3,4- de ]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Discovery of bipyridine amide derivatives targeting p RXRα-PLK1 interaction for anticancer therapy

Discovery and Synthesis of a Novel Series of Potent, Selective Inhibitors of the PI3Kα: 2-Alkyl-chromeno[4,3-c]pyrazol-4(2h)-one Derivatives.

Synthesis, Molecular Docking and Evaluation of Thiazolyl-Pyrazoline Derivatives As Egfr Tk Inhibitors and Potential Anticancer Agents